Radiotherapy of Oligometastatic Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Metastasis".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 13558
Special Issue Editor
Special Issue Information
Dear Colleagues,
The improvement of cancer survival, due to better oncology treatments and the concomitant widespread use of new-generation imaging, has been associated with an increasing number of patients diagnosed (after primary treatment or de novo) with oligometastatic disease. Systemic therapies, including chemotherapy, targeted therapy, immuno-therapy, and hormone-therapy, remain the standard approach for these cases. Due to the limited metastatic burden and frequently favorable outcomes, metastasis-directed therapies (MDTs) have been tested in retrospective studies and prospective trials as a therapeutic alternative to increase progression-free survival or to delay the utilization of systemic therapies in several settings.
In the specific scenario of oligometastatic disease, as postulated by Hellman and Weichselbaum, radiotherapy represents an attractive treatment option for the management of oligometastases. Radiotherapy has been increasingly implemented in clinical practice as an MDT strategy for the intensification of care in oligometastatic cancer patients. The MDRT (metastasis-directed radiotherapy) approach is mainly represented by stereotactic body radiotherapy (SBRT), also called stereotactic ablative radiotherapy (SABR), with or without systemic therapy. Furthermore, the evidence of advanced and focused radiotherapy in this context is increasing: the recently updated results of the SABRCOMET trial confirm a survival advantage with the addition of SBRT to the standard-of-care. These results are in line with those of several other studies with consistent data confirming the promising application of SBRT in the field of oligometastases. However, several criticisms and issues to resolve are still objects of debate. Even if MDRT has been largely adopted in oligometastasis clinical practice, a large variability remains in terms of the definition of the ideal candidate, the radiation treatment doses and schedules to adopt, the volumes to irradiate, and treatment planning optimization to use.
The goal of this Special Issue is to highlight the role of radiotherapy in oligometastatic cancer, especially covering clinical aspects that advance our understanding of targeting this complex metastatic disease with radiotherapy.
Prof. Dr. Filippo Alongi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- SBRT
- SABR
- oligometastases
- oligorecurrence
- oligoprogression
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.